MeiraGTx Holdings plc

NASDAQ•MGTX

CEO: Dr. Alexandria Forbes Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2018-06-08

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

联系方式

450 East 29th Street, 14th Floor, New York, NY, 10016, United States

646-860-7985

meiragtx.com

市值

$562.63M

市盈率 (TTM)

-3.4

17.8

股息率

52周最高

$9.73

52周最低

$4.55

52周范围

47%

排名67Top 97.6%

1.4

F-Score

改良版 Piotroski 分析

基于 9 年期基本面

疲弱 • 1.4 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2017-2025

财务仪表盘

Q3 2025 数据

营业收入

$410.00K-96.24%

近4季度走势

每股收益

-$0.62+12.73%

近4季度走势

自由现金流

-$12.83M-50.20%

近4季度走势

2025 Q3 财报亮点

核心亮点

Hologen Strategic Collaboration Closed Received $28.0M deposit from Hologen; joint venture established for AAV-GAD Parkinson's program development.

Lilly Ophthalmology Deal Signed Secured exclusive worldwide rights for AAV-AIPL1; eligible for $75.0M upfront payment plus $400.0M milestones.

Service Revenue Significantly Decreased Nine-month service revenue fell $5.9M to $6.0M USD as PPQ services under Asset Purchase Agreement substantially completed.

RMAT Designations Secured Received FDA RMAT designation for AAV-hAQP1 (xerostomia) and AAV-GAD (Parkinson's), potentially accelerating review timelines.

关注风险

Persistent Operating Losses Incurred Accumulated deficit reached $831.3M USD as of September 30, 2025; expects substantial losses for foreseeable future.

Future Capital Requirements High Requires substantial additional financing for development; failure to raise capital risks delaying or eliminating key research and development programs.

Gene Therapy Regulatory Uncertainty Novel gene therapy platform faces uncertain regulatory landscape; predicting development time and cost remains difficult.

Manufacturing Capacity Constraints Reliance on third-party plasmid suppliers and internal facilities carries risk of delays or inability to meet regulatory requirements or commercial scale.

前瞻展望

Advance AAV-GAD Phase 3 Study Engaging global sites to initiate Phase 3 study for AAV-GAD Parkinson's treatment in the coming months following RMAT designation.

AAV-hAQP1 Pivotal Data Expected Phase 2 AQUAx2 study enrolling final cohorts; potential pivotal data readout supporting BLA filing targeted for early 2027.

Expand Riboswitch Platform Into Clinic Progressing first riboswitch program (human leptin) into clinic; demonstrated dose-response efficacy in mouse models over one year.

Cash Runway Extended to 2027 Estimated cash sufficient to fund operations into second half of 2027, supported by Lilly and Hologen funding milestones.

同行对比

营业收入 (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

RGNX

$170.44M

+104.5%

毛利率 (最新季度)

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

ATXS

100.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
ERAS	$4.81B	-34.5	-33.1%	11.5%
IOVA	$1.52B	-4.8	-54.5%	5.3%
KOD	$1.33B	-6.1	-246.2%	28.5%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-73.2%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年3月12日

每股收益:-$0.60

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据